To disseminate the findings generated in VALUE-Dx by using various forms of communication and educational activities and publications at all levels of stakeholder platforms to promote their uptake and implementation in daily clinical practice and policy
To develop innovative, effective ways to disseminate information for creating awareness of optimal diagnosis and prognosis of CA-ARTI to prevent unnecessary prescription and use of antibiotics, to improve coverage with antibiotics, and thus limit antibiotic resistance and associated health and socioeconomic impacts
To develop and to tailor materials to support the adoption of CA-ARTI-Dx in European community care settings
Meet Dr. Füsun Can, a medical doctor and professor in Istanbul. She leads a multidisciplinary team focused on antibiotic resistance research. With expertise in virology and a commitment to collaborative efforts, Dr. Can’s work extends beyond the laboratory, aiming to address emerging infectious disease challenges across Turkey.
https://www.value-dx.eu/wp-content/uploads/2024/04/Picture-Fusun-scaled.jpg24542560Leandrahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngLeandra2024-04-15 15:05:072024-04-16 13:50:39AMR expert interview with Dr. Füsun Can
https://www.value-dx.eu/wp-content/uploads/2023/08/shutterstock_1714915966-scaled.jpg14212560Leandrahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngLeandra2024-02-02 15:53:102024-02-02 15:53:10VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections
https://www.value-dx.eu/wp-content/uploads/2023/11/Screenshot-2023-11-22-at-13.37.48.png656741Leandrahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngLeandra2023-11-23 14:04:222023-11-23 14:05:15Progress and insights from the PRUDENCE and ADEQUATE trials